KEPZAVYQ
Live / Registered — Registered (as of 15 Oct 2024)
What this means for you
Registered since 15 Oct 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97541157
- Registration number
- 7532813
- Mark type
- Stylized text
- Filed
- 09 Aug 2022
- Published for opposition
- 30 Jul 2024
- Registered
- 15 Oct 2024
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Brentford, Middlesex, GB
Prosecution history
- 15 Oct 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 15 Oct 2024 — REGISTERED-PRINCIPAL REGISTER
- 30 Jul 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 30 Jul 2024 — PUBLISHED FOR OPPOSITION
- 10 Jul 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 24 Jun 2024 — CASE RETURNED TO EXAMINATION
- 24 Jun 2024 — NOTICE OF ALLOWANCE CANCELLED
- 12 Jun 2024 — JURISDICTION RESTORED TO EXAMINING ATTORNEY
- 12 Jun 2024 — PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
- 10 Jun 2024 — ASSIGNED TO PETITION STAFF
- 01 May 2024 — TEAS PETITION TO AMEND BASIS RECEIVED
- 05 Mar 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Mar 2024 — SOU EXTENSION 1 GRANTED
- 04 Mar 2024 — SOU EXTENSION 1 FILED
- 04 Mar 2024 — SOU TEAS EXTENSION RECEIVED